Angiotensin-converting enzyme (ACE) inhibitors have been shown to reduce cardiovascular risk in different groups of patients. Whether these effects can be generalized to the broad group of patients with vascular disease is unknown. Therefore, we undertook a combined analysis using individual data from ADVANCE, EUROPA, and PROGRESS to determine the consistency of the treatment effect of perindopril-based regimen in patients with vascular disease or at high risk of vascular disease.
Introduction
Clinical trials have demonstrated the efficacy of angiotensinconverting enzyme (ACE)-inhibitors in specific groups of patients at risk of cardiovascular events. 1 -9 Nowadays, the use of ACE-inhibitors is recommended in guidelines on the management of hypertension, stable coronary artery disease (CAD), myocardial infarction (MI), and heart failure. 10 -15 The beneficial effect of ACE-inhibitors is related, at least in part, to the blood pressure (BP)-lowering effects. However, ACE-inhibitors may have many valuable protective properties quite apart from BP lowering. Especially, perindopril has been extensively investigated in this regard and has been shown to improve endothelial function and neurohumoral balance, and inhibit remodelling of the coronary arteries. 16 -19 Since, the BPLTTC has demonstrated that BP-independent effects of ACE-inhibitor-based regimens do contribute to the reduction in CAD, 20, 21 it becomes more important to base decisions on the treatment of individual patients, on the assessment of total cardiovascular risk, rather than on arbitrary cut-off points for single risk factors such as BP. Most of the evidence currently available has been obtained from studies conducted in patient populations with vascular disease in a single vascular territory or with a metabolic disorder such as diabetes.
There is, therefore, a need for a broadly based study pooling individual patient data from patient populations with a wider spectrum of vascular disease. For this purpose, we undertook a combined analysis of the individual data from trials of perindopril-based regimens in patients with diabetes, CAD, and cerebrovascular disease. 7 -9 We investigated the treatment effect on clinical endpoints and their consistency in patient subgroups.
Methods
The methodological principles that lie behind a combined analysis of randomized clinical trials based on data from individual patients have been described in detail. 22 We therefore only briefly describe the applied methods of trial selection, data-management, endpoint definitions, and statistical analysis.
Trial selection
We obtained data from the ADVANCE, EUROPA, and PROGRESS studies that are the three main large trials with a regimen based primarily on the ACE-inhibitor perindopril. The ASCOT-BPLA was not selected because the combined treatment regimen was based on amlodipine with the addition of perindopril so that it was impossible to make unbiased estimates for the treatment effect of perindopril. 23 Since all trials studied a regimen based on the same agent, perindopril, we had the opportunity to include individual data in this combined analysis, which made important subgroup analyses possible at the patient level. The types of patients included in these studies were different in their primary diagnoses, but since atherosclerosis and vascular disease is not restricted to a single vascular bed, we conclude that these patients are at least homogenous in having vascular disease or being at a high risk of vascular disease. The combined data set consisted of 29 463 patients, who were followed for on average 4 years. We had full access to all individual data of the trials. After datamerging, data were tested carefully for completeness, internal consistency of patients' records, and consistency with the published reports. Table 1 shows the main inclusion and exclusion criteria, outcomes, recruitment, and follow-up of the three trials.
Outcomes
In this analysis, we assessed all-cause mortality, cardiovascular mortality, fatal and non-fatal stroke, revascularization, non-fatal MI, hospital admission for heart failure, and major cardiovascular endpoints as a composite of cardiovascular mortality, MI, and stroke. The definitions of endpoints in these trials were carefully checked and were not essentially different across the trials. Where there were slight differences in endpoints or thresholds, we did not try to match everything, since that this is often impossible retrospectively. Moreover, this is not necessary since in each study the treatment effects were compared within rigorously randomized and well-balanced treatment groups. Since we know that heterogeneity in an endpoint definition will not lead to invalid results, we applied the trial-specific definition of MI for practical reasons. 24 Several endpoints were not presented in the main papers of the ADVANCE and PROGRESS trials, for example, the data for revascularization. For a comprehensive and comparable analysis, these endpoints were included.
Subgroups
We tested the consistency of the treatment effect of perindopril-based regimens in relation to baseline clinical characteristics [gender, agecategories (,60; 60 -70; .70 years), mean age (,63; .63 years) hypertension, diabetes, cerebrovascular accident (CVA)/transient ischaemic attack (TIA), and revascularization] and in relation to concomitant medication (anti-platelet agents, lipid-lowering agents, b-blockers, diuretics, and calcium antagonists). We investigated the treatment effect of perindopril-based regimen on the outcomes according to BP levels at baseline (first screening visit). Ordinal categories of systolic BP and diastolic BP were defined as follows: systolic BP ,120, 120 -139, 140-159, and 160 mmHg; diastolic BP ,80, 80 -90, 90 -100, and 100 mmHg. Further, we investigated whether the treatment effect was independent of the level of BP-reduction by active treatment. All patients were treated during run-in period of 4 weeks. Blood pressure reduction was calculated as the difference between the baseline measurement and the end of the run-in period.
We accounted for the difference in dosage of perindopril (EUROPA 4 -8 mg, ADVANCE and PROGRESS 2 -4 mg) and combination with indapamide (ADVANCE and PROGRESS 2.5 mg) in all analyses. We emphasize that for analyses of BP reduction during run-in, baseline BP was added as continuous variable in the model to adjust for the starting level of BP before initiation of ACE-inhibitor treatment (avoids regression to the mean).
Statistical analysis
The statistical principles used in these analyses have been described previously in the main papers of the trials for the assessment of reduction in outcomes. Although baseline characteristics are well balanced between the randomized groups for each trial, we choose to perform a multivariate Cox regression analysis because of the difference between the studies themselves and because adjustment for baseline characteristics, even when randomized, is recommended in clinical trials. 25 By multivariate analysis, confidence intervals (CIs) will widen slightly (although compensated by the large number of patients) but the validity will increase which is most important. 
Results
The baseline characteristics of the total study population (n ¼ 29 463) are summarized in 
Clinical endpoints
The perindopril-based regimen was associated with a significantly lower cumulative incidence of all-cause mortality as well as major cardiovascular events when compared with placebo in the Kaplan-Meier analysis (both log ranks P-value ,0.001) as presented in Figure 1 . During a mean follow-up of 4.0 years (SD 0.8), there were 1089 deaths (7.4%) in the active treatment group and 1210 (8.2%) in the placebo group (HR 0.89; 95% CI 0.82-0.96; P-value ¼ 0.006). No heterogeneity between the studies was observed (P for interaction 0.56). Results for the other endpoints were comparable and are presented in Table 3 . Significant heterogeneity in the treatment effect between the studies was observed for heart failure admission (no effect in ADVANCE) and for fatal and non-fatal stroke (no effect in ADVANCE or EUROPA 
Blood pressure
The perindopril-based treatment regimen was associated with lower major cardiovascular event rates across all strata of systolic BP as well as diastolic BP, although in the lower systolic BP categories, the treatment effect estimates did not reach significance. Also, the relative treatment benefit was somewhat larger at higher diastolic BP levels (P for interaction ,0.001) (Figure 2A) . During the run-in period of 4 weeks, all patients were treated with perindopril (n ¼ 29 463) and BP decreased from 142/82 to 134/78 mmHg. The average BP reduction during run-in was 8.3/ 3.8 mmHg and during follow-up 5.4/2.3 mmHg. The BP reduction during run-in was comparable in each of the three trials (ADVANCE: 8/3 mmHg; EUROPA 9/4 mmHg; and PROGRESS 9/ 5 mmHg). The perindopril-based regimen reduced the incidence of major cardiovascular events in all categories of BP reduction during run-in ( Figure 2B) . However, the relative treatment benefit was somewhat larger in patients with a higher diastolic BP reduction during run-in (P for interaction 0.05).
Subgroups
The treatment effect of the perindopril-based regimen was independent of baseline clinical characteristics and concomitant medication ( Figure 3) . In subgroups of age and diabetes mellitus, P for interaction was, respectively, 0.07 and 0.06, but the perindopril-based regimen was associated with a significant positive treatment effect in patients with or without diabetes, and in patients aged ,60, 60-70, or .70 years. A dichotomized age variable, at the median age of the study population (63.0 years), resulted in similar treatment effect estimates (age 63: HR 0.78; 95% CI 0.69-0.87 and age .63: HR 0.85; 95% CI 0.78-0.93). For combinations of concomitant medication use compromising platelet-inhibitors, lipid-lowering agents, calcium antagonists, b-blockers, and diuretics use (none, one, two, three, four, or all of the mentioned medication use), HRs were similar as shown for the individual medications and no heterogeneity in the treatment effect was observed ( Figure 3 , data not shown). Results for other study endpoints were similar and no heterogeneity was observed. Significant heterogeneity between the studies was observed for fatal and non-fatal stroke, non-fatal MI, and hospital admission for heart failure ( Table 3) . In a separate analysis of single therapy by perindopril (n ¼ 14 779), by excluding all indapamide use, heterogeneity vanished (P . 0.10). Single therapy was no longer associated with a significant treatment benefit on fatal and non-fatal stroke (HR 0.96; 95% CI 0.82 -1.12) (Figure 4) . In contrast, the effect on non-fatal MI and heart failure admissions increased to, respectively, HR 0. 
Discussion
The present analysis, based on individual data from 29 463 patients, demonstrates that a perindopril-based regimen reduces the risk of mortality and major cardiovascular events among patients with various levels of cardiovascular risk. Furthermore, the benefit was observed across a wide spectrum of baseline BP levels. Therefore, the use of ACE-inhibitors should be considered in all patients with established vascular disease or at high risk of vascular disease even in patients with normal BP levels.
A prior study, a meta-analysis, which studied three trials with similar type of patients with CAD (HOPE, EUROPA, and Figure 1 Kaplan-Meier analysis of cumulative incidence of all-cause mortality and major cardiovascular events (cardiovascular mortality, myocardial infarction, and stroke) in 29 463 patients. The x-axis corresponds to the duration of follow-up in years. The y-axis to the cumulative incidence of all-cause mortality (A) and major cardiovascular events in percentages (%) (B). The percentages along the lines correspond to the Kaplan -Meier estimates at 1, 2, 3, and 4 years of follow-up in patients allocated the perindopril-based regimen (red line) or placebo (black line). Below the graph, the number of events and the number of patients at risk during follow-up (per year) are presented.
Consistent cardiovascular protection with an ACE-inhibitor treatment regimen PEACE) showed a consistent treatment effect of ACE-inhibitors in reducing cardiovascular events. 26 The current analysis demonstrates clear evidence for a consistent cardiovascular protection in a broader range of patients with vascular disease including clear benefits in reducing death. These results confirm the generalizability of prior studies in separate patients' groups and support the provision of treatment, not on the basis of arbitrary cut-off points for BP, but rather on the assessment of absolute or total vascular risk, which is raised in patients with stable CAD, diabetes, and stroke as shown in EUROPA, ADVANCE, and PROGRESS. These results are consistent with the findings of the HOPE trial which studied the ACE-inhibitor ramipril. Cox regression multivariate analysis was used to calculate HRs and 95% CI adjusted for age, gender, hypertension, diabetes mellitus, smoking, history of MI, prior revascularization, prior CVA/TIA, use of b-blockers, lipid-lowering agents, anti-platelet agents, diuretics, calcium antagonists, indapamide, and perindopril dosage. The multivariate Cox model was applied for the results of the individual trials as well as the pooled analysis of individual data presented as 'total' (n ¼ 29 463) adjusted for the three trials. HR, hazard ratio; CI, confidence interval; MI, myocardial infarction. *In single therapy analysis, P for heterogeneity .0.10.
Significant interaction was observed for fatal and non-fatal stroke as a separate outcome ( Table 3) . Such heterogeneity can be related to differences across trials in the study medication, patient selection, or concomitant medication ( Table 2) . While ADVANCE and EUROPA showed low stroke rates and no treatment benefit for stroke, PROGRESS showed a significant reduction of 28% in stroke in patients with cerebrovascular disease. Therefore, the ACE-inhibitor-based treatment regimen was more effective in reducing recurrent stroke (PROGRESS) than in reducing incident stroke in patients without a history of cerebrovascular disease (EUROPA and ADVANCE). These benefits were contingent on the BP-lowering effect with additional indapamide use. Single therapy with perindopril was not associated with a significant reduction in the risk of stroke. Additional interaction was observed on the separate outcome of nonfatal MI and hospitalization for heart failure ( Table 3) , mainly caused by the lack of benefit in ADVANCE conducted in patients with DM but most without a history of macrovascular disease. In both cases, interaction was observed for cause-specific outcomes, however, there was no heterogeneity in reducing the over-arching endpoints of allcause mortality or the composite endpoint of cardiovascular Figure 2 (A) Treatment effect of perindopril-based regimen in relation to major cardiovascular diseases (cardiovascular mortality, MI, and stroke) according to baseline blood pressure (BP) strata. Forest plot of the treatment effect of the perindopril-based regimen at categories of baseline systolic BP (,120, 120 -139.9, 140-159.9, and 160 mmHg) and diastolic BP (,80, 80 -89.9, 90 -99.9, and 100 mmHg). Next to the forest plot, the HR and 95% CI are presented as well as the P-values for interaction. Cox regression multivariate analysis was used to calculate HRs and 95% CI adjusted the full model. Additionally, P-values for interaction were calculated by including an interaction term in the model using systolic and diastolic BP levels as continuous variable * treatment. HR, hazard ratio; CI, confidence interval. (B) Treatment effect of perindopril-based regimen in relation to major cardiovascular diseases (cardiovascular mortality, MI, and stroke) according to BP reduction levels. Forest plot of the treatment effect of the perindopril-based regimen at tertiles of systolic and diastolic BP reduction during the run-in period. Cox regression multivariate analysis was used to calculate HRs and 95% CI. We emphasize that these analyses were also corrected for the starting systolic and diastolic BP values before application of treatment in all patients. Additionally, P-values for interaction were calculated by including an interaction term in the model using systolic and diastolic BP reduction levels as continuous variable * treatment. MI, myocardial infarction; HR, hazard ratio; CI, confidence interval.
Consistent cardiovascular protection with an ACE-inhibitor treatment regimen mortality, MI, and stroke. In the analysis of single perindopril therapy, heterogeneity vanished and the risk reduction by single therapy improved for both outcomes.
Regarding BP, the findings from the BPLTTC already suggested some BP-dependent and some BP-independent effects of ACE-inhibitors on the risk of major coronary disease events by using tabular data. 20, 21, 27, 28 Now, we can confirm these findings in a large combined patient-level data analysis with access to individual BP measurements. We showed a lower major cardiovascular event rate across all strata of systolic and diastolic BPs, although not statistically significant for lower systolic BP strata, as well as across the tertiles of BP reduction during run-in. Patients with the highest diastolic BP or highest diastolic BP reduction experienced a somewhat larger relative treatment effect. Also the patients with the highest BP reduction remained on average also at lower BP during follow-up. The current study is unique and important because it studies the individual data of large trials across a broad range of vascular risk and is focused on one ACE-inhibitor. The use of individual data makes the results robust and provides a unique opportunity to detect the subgroups of patients who might (or might not) benefit the most from treatment. Furthermore, the ACE-inhibitor perindopril has several properties different from other agents in its class, being a long-acting (24 h), once-daily lipophilic ACE-inhibitor with high affinity for both tissue and circulating ACE. Tissue ACE affinity is related to specific anti-atheroscletic and anti-thrombotic effects, as well as improvements in endothelial function. 29 However, we acknowledge that the exact clinical meaning of these properties remains unknown, since ACE-inhibitors have not been prospectively compared with each other in studies.
Several limitations of this analysis can be noted. The trials differed in the patient selection, adjunctive therapy, and drug dosage. Therefore, we adjusted for perindopril dosage and indapamide use in all analyses and checked for interaction or heterogeneity among trials. This is unlikely to have affected our conclusions as discussed above. Furthermore, we acknowledge that the accuracy of the BP measurements in large trials and different hospital settings may be questioned. However, any inaccuracy would be equally distributed among randomized treatment groups and unlikely to affect our conclusions. Although, the patient populations in the three trials studied were different, it is well established that atherosclerotic vascular disease is a generalized process not restricted to a single vascular bed. Therefore, we believe that our pooled patient sample is broadly representative of patients with established vascular disease at high risk of vascular disease across the world. Despite the differences between the trials, the outcomes are consistent with findings from other different meta-analyses on patients without heart failure 26,28,30,31 and patients with heart failure. 32 The currents study demonstrates that perindopril-based regimens (perindopril in part of the patients combined with indapamide) reduce death in patients with vascular disease. The consistency of the relative effects across subgroups indicates that the absolute benefits conferred by treatment will be determined mainly by each patient's future risk of vascular complications, rather than their initial level of BP alone or other risk factors. These results support the provision of ACE-inhibitor-based treatment, not on the basis of arbitrary cut-off points for BP, but rather on the assessment of vascular risk, which is raised in patients with stable CAD, diabetes, and stroke. This approach, based on total cardiovascular risk, should form the basis for the recommendations for treatment in the revision of the major national and international guidelines. Consistent cardiovascular protection with an ACE-inhibitor treatment regimen
